10556229.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 8	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 9	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 10	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 11	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 12	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 13	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 14	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 15	DEC 18	CA/CAplus patent kind codes updated
NEWS 16	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 17	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 18	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 19	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 20	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 21	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 22	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:39:23 ON 17 JAN 2007

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:39:35 ON 17 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 JAN 2007 HIGHEST RN 917560-96-4
DICTIONARY FILE UPDATES: 16 JAN 2007 HIGHEST RN 917560-96-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10556229.str





chain nodes :
10 11 12 13 14 15 18
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
6-10 10-11 11-12 12-13 12-15 13-14 13-18
ring bonds :
1-2 1-7 2-3 3-4 4-8 5-6 5-9 6-7 7-8 8-9
exact/norm bonds :
5-6 5-9 6-7 6-10 8-9 12-13 12-15 13-18
exact bonds :
10-11 11-12 13-14
normalized bonds :
1-2 1-7 2-3 3-4 4-8 7-8
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 18:CLASS

L1 STRUCTURE UPLOADED

=> D L1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> S L1
SAMPLE SEARCH INITIATED 13:39:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1117 TO ITERATE

```
100.0% PROCESSED     1117 ITERATIONS                                47 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        20335 TO    24345
PROJECTED ANSWERS:             529 TO     1351

L2            47 SEA SSS SAM L1

=> S L1 SSS FULL
FULL SEARCH INITIATED 13:40:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    22839 TO ITERATE

100.0% PROCESSED    22839 ITERATIONS                               947 ANSWERS
SEARCH TIME: 00.00.03

L3           947 SEA SSS FUL L1

=> FIL HCAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             172.10     172.31

FILE 'HCAPLUS' ENTERED AT 13:40:18 ON 17 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 17 Jan 2007  VOL 146 ISS 4
FILE LAST UPDATED: 16 Jan 2007  (20070116/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> S L3
L4           102 L3

=> S L4 AND THU
            158 THU
        2376538 THUS
        2376679 THU
                (THU OR THUS)
L5           39 L4 AND THU

=> S L5 AND VRI
```

```
            153 VRI
              1 VRIS
            153 VRI
                  (VRI OR VRIS)
L6            0 L5 AND VRI

=> S L5 AND VR1
           1416 VR1
L7            0 L5 AND VR1

=> S L5 AND PY,=2003
'2003' NOT A VALID FIELD CODE
              0 PY,=2003
L8            0 L5 AND PY,=2003

=> S L5 AND PY<=2003
      23914968 PY<=2003
L9           32 L5 AND PY<=2003

=> D L9 IBIB AGS HITSTR 1-15
'AGS' IS NOT A VALID FORMAT FOR FILE 'HCAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
```

```
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):END

=> D HIS

     (FILE 'HOME' ENTERED AT 13:39:23 ON 17 JAN 2007)

     FILE 'REGISTRY' ENTERED AT 13:39:35 ON 17 JAN 2007
L1             STRUCTURE UPLOADED
L2              47 S L1
L3             947 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 13:40:18 ON 17 JAN 2007
L4             102 S L3
L5              39 S L4 AND THU
L6               0 S L5 AND VRI
L7               0 S L5 AND VR1
L8               0 S L5 AND PY,=2003
L9              32 S L5 AND PY<=2003

=> D L9 IBIB ABS HITSTR 1-15

L9   ANSWER 1 OF 32  HCAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2003:633705  HCAPLUS
DOCUMENT NUMBER:          139:180070
TITLE:                    Preparation of 2-(4-amino-1,2,5-oxadiazol-3-
                          yl)benzimidazoles as inhibitors of GSK-3
INVENTOR(S):              Harbeson, Scott L.; Arnost, Michael J.; Green, Jeremy;
                          Savic, Vladimir
PATENT ASSIGNEE(S):       Vertex Pharmaceuticals Incorporated, USA
SOURCE:                   PCT Int. Appl., 93 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
```

```
     WO 2003066629          A2     20030814     WO 2003-US3655          20030206 <--
     WO 2003066629          A3     20031030
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
             UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2475633             A1     20030814     CA 2003-2475633         20030206 <--
     AU 2003215087          A1     20030902     AU 2003-215087          20030206 <--
     US 2004034037          A1     20040219     US 2003-360535          20030206
     EP 1472245             A2     20041103     EP 2003-710903          20030206
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2005526028          T      20050902     JP 2003-566002          20030206
     NO 2004003726          A      20041108     NO 2004-3726            20040906
PRIORITY APPLN. INFO.:                           US 2002-354843P      P  20020206
                                                 WO 2003-US3655       W  20030206

OTHER SOURCE(S):          MARPAT 139:180070
GI
```



I



II

AB The title compds. [I; ring A = (un)substituted 5-7 membered (un)saturated ring having 0-3 heteroatoms, and wherein ring A is optionally fused to 5-8 membered ring having 0-3 heteroatoms; ring B = (un)substituted 5-6 membered ring having 0-4 heteroatoms; W = N, CR4; X = N, CH (wherein at least one of W and X = N); R3 = TCN, LR; T = a bond, alkylidene; L = a bond, alkylidene wherein up to two methylene units of L are replaced by O, S, CO, etc.; R4 = LR, halo, TNO2, TCN; R = H, alkyl, aryl, etc.], useful as inhibitors of GSK-3 and Lck protein kinases (biol. data given) for treating and preventing various disorders, such as diabetes, Alzheimer's disease, and transplant rejection, were prepared Thus, reacting 1,2-phenylenediamine with Me 4-aminofurazan-3-carboximidate in the presence of AcOH in MeOH afforded 76% II. A pharmaceutical composition comprising the title compound I, was claimed.

IT 581081-66-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazoles as inhibitors of GSK-3)

RN 581081-66-5 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 2-(4-amino-1,2,5-oxadiazol-3-yl)-N-methyl- (9CI) (CA INDEX NAME)



IT 384860-19-9P 581081-53-0P 581081-61-0P
581081-68-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazoles as inhibitors of GSK-3)

RN 384860-19-9 HCAPLUS
CN 1H-Benzimidazole-1-acetamide, 2-(4-amino-1,2,5-oxadiazol-3-yl)-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 581081-53-0 HCAPLUS
CN 1H-Benzimidazole-1-acetamide, 2-(4-amino-1,2,5-oxadiazol-3-yl)-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 581081-61-0 HCAPLUS
CN 1H-Benzimidazole-1-acetamide, N-(2-aminoethyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)



RN 581081-68-7 HCAPLUS
CN 1H-Benzimidazole-1-acetamide, 2-(4-amino-1,2,5-oxadiazol-3-yl)-N-(2-amino-2-oxoethyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 2 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:185081 HCAPLUS
DOCUMENT NUMBER: 136:247498
TITLE: Acylaminoalkylpiperidines as chemokine and H1 receptor antagonists
INVENTOR(S): Sanganee, Hitesh; Springthorpe, Brian
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020484	A1	20020314	WO 2001-SE1869	20010830 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001084584	A5	20020322	AU 2001-84584	20010830 <--
EP 1322611	A1	20030702	EP 2001-963655	20010830 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004508355	T	20040318	JP 2002-525106	20010830

US 2004102432 A1 20040527 US 2003-344758 20030213
PRIORITY APPLN. INFO.: GB 2000-21670 A 20000904
WO 2001-SE1869 W 20010830
OTHER SOURCE(S): MARPAT 136:247498
GI



I



II

AB Title compds. I [R1 = (un)substituted Ph; n = 1-4; m = 0, 1; when m = 0, q = 0; when m = 1, q = 1-4; R2, R3 = H, alkyl, R4 = H, alkyl, cycloalkylalkyl, R5 = substituted cyclic, heterocyclic; R2 = (un)substituted Ph, R3 = H, alkyl, R4 = H, alkyl, alkoxy, R5 = substituted cyclic, heterocyclic] were prepared for use as chemokine and H1 receptor antagonists in the treatment of asthma and rhinitis (no data). Thus, 3,4-Cl2C6H3OH was treated with 1-tert.-butoxycarbonyl-4-piperidinol, deblocked, treated with Br(CH2)3NHBoc, and deblocked to give the piperidine II as its hydrochloride.

IT 404030-44-0P 404030-45-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylaminoalkylpiperidines as chemokine and H1 receptor antagonists)

RN 404030-44-0 HCAPLUS
CN 1H-Benzimidazole-1-acetamide, N-[2-[4-(3,4-dichlorophenoxy)-1-piperidinyl]ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 404030-45-1 HCAPLUS
CN 1H-Benzimidazole-1-acetamide, N-[2-[4-(3,4-dichlorophenoxy)-1-piperidinyl]ethyl]-2-(ethylthio)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:923615 HCAPLUS
DOCUMENT NUMBER: 136:37623
TITLE: Preparation of imidazopyridine and imidazopyrimidine antiviral agents
INVENTOR(S): Yu, Kuo-Long; Civiello, Rita L.; Combrink, Keith D.; Gulgeze, Hatice Belgin; Sin, Ny; Wang, Xiangdong; Meanwell, Nicholas A.; Venables, Brian Lee
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 196 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 2001095910	A1	20011220	WO 2001-US14775		20010508	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG						
US 2002016309	A1	20020207	US 2001-840279		20010423	<--
US 6489338	B2	20021203				
CA 2412327	A1	20011220	CA 2001-2412327		20010508	<--
BR 2001011569	A	20030429	BR 2001-11569		20010508	<--
EP 1311268	A1	20030521	EP 2001-952114		20010508	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
JP 2004503501	T	20040205	JP 2002-510088		20010508	
HU 200400766	A2	20040728	HU 2004-766		20010508	
NZ 523566	A	20040827	NZ 2001-523566		20010508	
IN 2002MN01766	A	20050204	IN 2002-MN1766		20021210	
NO 2002005977	A	20030129	NO 2002-5977		20021212	<--
ZA 2002010104	A	20040312	ZA 2002-10104		20021212	
PRIORITY APPLN. INFO.:			US 2000-211447P	P	20000613	
			US 2001-263363P	P	20010122	
			WO 2001-US14775	W	20010508	

OTHER SOURCE(S): MARPAT 136:37623
GI



I



II

AB The title compds. [I; W = O, S; R1 = (CR'R'')nX; X = H, alkyl, cycloalkyl, etc.; n = 2-6; R2 = H, alkyl, cycloalkyl, etc.; R3-R6 = H, halo, alkyl, etc.; A, B, E, D = CH, CQ, N, NO; provided at least one of A, B, E or D is not CH or CQ; Q = halo, alkyl, alkyl substituted with 1-3 halogen atoms; R', R'' = H, alkyl, cycloalkyl, etc.], useful in the treatment of viral infections, more particularly, for the treatment of respiratory syncytial virus infection, were prepared Thus, reacting I [W = O; R1 = (CH2)3NH2; R2 = cyclopropyl; R3-R6 = H; E = N; A, B, D = CH] (preparation given) with N-chloroacetylurethane in the presence of Na2CO3 in MeCN afforded 39% II.TFA. The compds. I showed antiviral activity against RSV with EC50's between 50 μM and 0.001 μM vs. Ribavirin with an EC50 of 3 μM.

IT 380603-71-4P 380603-73-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridine and imidazopyrimidine antiviral agents)

RN 380603-71-4 HCAPLUS

CN 1H-Benzimidazole-1-butanamide, 2-[(1-cyclopropyl-1,2-dihydro-2-oxo-3H-imidazo[4,5-c]pyridin-3-yl)methyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 380603-73-6 HCAPLUS

CN 1H-Benzimidazole-1-butanamide, 2-[(1-cyclopropyl-1,2-dihydro-2-oxo-3H-imidazo[4,5-c]pyridin-3-yl)methyl]-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:668212 HCAPLUS
DOCUMENT NUMBER: 135:226999
TITLE: Preparation of 2-azolylpyrrolidine or -piperidine derivatives having neurite outgrowth activity
INVENTOR(S): Kato, Susumu; Ueno, Hiroshi; Kondo, Wataru
PATENT ASSIGNEE(S): Japan Tobacco, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 81 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
JP 2001247569	A	20010911	JP 2000-236882		20000804	<--
PRIORITY APPLN. INFO.:			JP 1999-228938	A	19990812	
			JP 1999-375867	A	19991228	

OTHER SOURCE(S): MARPAT 135:226999
GI



I

Q= 

Q^1= 

Q^2= 

Q^3= 

Q^4= 

Q^5= 

Q^6= 

AB The title compds. [I; R1 = H, (un)substituted C3-10 cycloalkyl, C6-12 aryl, or 5- to 6-membered heterocyclyl containing 1-3 heteroatoms selected from O, S, and N; R2 = C1-6 alkyl, C3-10 cycloalkyl, C6-12 aryl, or 5- to 6-membered heterocyclyl containing 1-3 heteroatoms selected from O, S, and N; R21 = H, C1-6 alkyl; X1 = single bond, O, S, SO, SO2, CH:CH, CO, CO2, NR10, CONR10, NR10CO, NR11CONR10, NR10SO2, SO2NR10, CR10R11 [wherein R10 = H, (CH2)nR12 (wherein n = 1-4; R12 = C3-10 cycloalkyl, C6-12 aryl, or 5- to 6-membered heterocyclyl containing 1-3 heteroatoms selected from O, S, and N); R11 = H, C1-6 alkyl]; Y1 = arylene, heteroarylene, (CH2)p (wherein p = 0, 1-4); X2 = SO2, COCO, CO2, CO, C(S), CONR14, C(S)NR14 (wherein R14 = H, C1-6 alkyl); Y = (CH2)r (wherein r = 0, 1-3), CH:CH; m = 0, 1-4; ring B = Q - Q6 [wherein R3 = H, C1-6 alkyl; X4 = O, S, NR4 (wherein R4 = H, C1-6 alkyl)], (un)substituted condensed heterocyclyl], salts thereof, or their hydrates or prodrugs are prepared These compds. are superior in serum stability and can be administered orally and are useful for the treatment and/or prevention of diseases accompanied by nerve injury or neurodegeneration, e.g. diabetic nerve disorders, neuropathy, nerve cutting, amyotrophic lateral sclerosis (ALC), multiple sclerosis, Alzheimer's diseases, Parkinson's diseases, Huntington chorea, and spinal code injury. Thus, 464 mg 7-chloronaphth-2-ylsulfonyl chloride was added to a solution of 507 mg 5-(5-benzyloxycarbonylaminomethyl-1,3,4-thiadiazol-2-yl)pyrrolidine (preparation given) in pyridine and stirred at room temperature for 3 h to give 706 mg 1-(7-chloronaphthalen-2-ylsulfonyl)-2-(5-benzyloxycarbonylaminomethyl-1,3,4-thiadiazol-2-yl)pyrrolidine which (678 mg) was treated with 25% HBr-AcOH at room temperature for 1 h and treated with diisopropyl ether for precipitating crystals, followed by neutralizing the precipitated crystals with 1 N aqueous NaOH and extraction with CH2Cl2 to give 472 mg 1-(7-chloronaphthalen-2-ylsulfonyl)-2-(5-aminomethyl-1,3,4-thiadiazol-2-yl)pyrrolidine. To a solution of the latter compound (164 mg) in 2 mL pyridine was added 143 mg nicotinoyl chloride hydrochloride and stirred at room temperature for 30 min to give 183 mg N-[5-[1-(7-chloronaphthalene-2-sulfonyl)pyrrolidin-2-yl]-1,3,4-thiadiazol-2-yl]methyl-3-pyridinecarboxamide (II). II at 10 nM in vitro exhibited the enhancement of the NGF-induced neurite outgrowth in PC12h cells equivalent to that of 100 nM FK-506.

IT 359802-97-4P 359802-98-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-azolylpyrrolidine or -piperidine derivs. having neurite outgrowth activity for treatment and/or prevention of nerve injury or neurodegenerative diseases)

RN 359802-97-4 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[1-[2-oxo-2-[[2-(3-pyridinyl)ethyl]amino]ethyl]-1H-benzimidazol-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 359802-98-5 HCAPLUS
CN 1H-Benzimidazole-1-acetamide, 2-[1-[(4-chlorophenyl)sulfonyl]-2-pyrrolidinyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 5 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:241749 HCAPLUS
DOCUMENT NUMBER: 134:266310
TITLE: Preparation of 2-aryl-benzimidazoles for treating neoplasia
INVENTOR(S): Sperl, Gerhard; Ixkes, Ulrich; Pamukcu, Rifat; Piazza, Gary A.
PATENT ASSIGNEE(S): Cell Pathways, Inc., USA
SOURCE: U.S., 12 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6211177	B1	20010403	US 1998-200378	19981124 <--
PRIORITY APPLN. INFO.:			US 1998-200378	19981124

OTHER SOURCE(S): MARPAT 134:266310
GI



I

AB The title compds. [I; R1 = H, alkyl, (un)substituted CH2Ph, etc.; R2 = (un)substituted Ph, CH2Ph, pyridyl, etc.; R3 = halo, alkoxy, alkyl, etc.; n = 0-2], useful for inhibiting neoplasia, particularly cancerous and precancerous lesions (no data), were prepared Thus, reacting 1,2-phenylenediamine with 3,4,5-trimethoxybenzaldehyde in the presence of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone in MeCN afforded 14% I [R1, R3 = H; R2 = 3,4,5-(MeO)3C6H2].

IT 332015-21-1P 332015-24-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-aryl-benzimidazoles for treating neoplasia)

RN 332015-21-1 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 5-methoxy-N-(phenylmethyl)-2-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 332015-24-4 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 5-fluoro-N-(phenylmethyl)-2-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:149048 HCAPLUS
DOCUMENT NUMBER: 134:193454
TITLE: Preparation of N-(2-benzimidazolyl)-1,4-diazepanes as histamine and tachykinin receptor antagonists
INVENTOR(S): Kane, John M.; Maynard, George D.; Burkholder, Timothy P.; Bratton, Larry D.; Dalton, Christopher R.; Kudlacz, Elizabeth M.; Santiago, Braulio
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA
SOURCE: U.S., 108 pp., Cont.-in-part of U.S. Ser. No. 736,411.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6194406	B1	20010227	US 1997-513847	19971029 <--
US 2001034343	A1	20011025	US 2000-739741	20001218 <--
US 6423704	B2	20020723		

PRIORITY APPLN. INFO.:
US 1995-70907P P 19951220
US 1996-736411 B2 19961024
US 1997-513847 A2 19971029
OTHER SOURCE(S): MARPAT 134:193454
GI



I

AB Title compds. [I; R = R5Z5Z4(CH2)m; R1 = (CH2)rR4; R2 = Z3(CH2)nR3; R3 = (un)substituted Ph, -1,3-benzodioxol-5-yl, -1,4-benodioxan-6-yl; R4 = (un)substituted Ph, -naphthyl, pyridinyl, -thienyl; R5 = H, (oxa)alkyl, (hetero)arylalkyl, etc.; Z,Z2 = CH2 or CO; Z1 = CH2 or CH2CH2; Z3 = CH2, CHMe, CO; Z4 = 1,4-diazepan-1,4-diyl; Z5 = (un)substituted benzimidazole-1,2-diyl; m = 2 or 3; n,r = 0 or 1] were prepared as histamine and tachykinin receptor antagonists (no data). Thus, e.g., I [R = 2-[4-[1-(2-ethoxyethyl)benzimidazol-2-yl][1,4]diazepan-1-yl]ethyl, R1 = 3,4-(MeO)2C6H3, R2 = COC6H2(OMe)3-3,4,5, Z = Z1 = Z2 = CH2] was prepared
IT 192941-18-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzimidazolyldiazepanes as antiallergics and antiinflammatories)
RN 192941-18-7 HCAPLUS
CN 1H-1,4-Diazepine-1-carboxylic acid, hexahydro-4-[1-[2-(methylamino)-2-oxoethyl]-1H-benzimidazol-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 192941-57-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(precursor; preparation of benzimidazolyldiazepanes as antiallergics and antiinflammatories)
RN 192941-57-4 HCAPLUS
CN 1H-Benzimidazole-1-acetamide, 2-(hexahydro-1H-1,4-diazepin-1-yl)-N-methyl-, monohydriodide (9CI) (CA INDEX NAME)



● HI

IT 192939-87-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzimidazolyldiazepanes as antiallergics and antiinflammatories)
RN 192939-87-0 HCAPLUS
CN 1H-Benzimidazole-1-acetamide, 2-[hexahydro-4-[2-[3-phenyl-1-(3,4,5-trimethoxybenzoyl)-3-pyrrolidinyl]ethyl]-1H-1,4-diazepin-1-yl]-N-methyl-(9CI) (CA INDEX NAME)



IT 327995-85-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazolyldiazepanes as antiallergics and antiinflammatories)
RN 327995-85-7 HCAPLUS
CN 1H-Benzimidazole-1-acetamide, 2-[hexahydro-4-[2-[3-phenyl-1-(3,4,5-trimethoxybenzoyl)-3-pyrrolidinyl]ethyl]-1H-1,4-diazepin-1-yl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:115088 HCAPLUS
DOCUMENT NUMBER: 134:178141
TITLE: Preparation of oxoazacycloalkanes and analogs
INVENTOR(S): Hulme, Christopher; Morton, George C.; Salvino, Joseph M.; Labaudiniere, Richard F.; Mason, Helen J.; Morrissette, Mathew M.; Ma, Liang; Cherrier, Marie-Pierre
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Products, Inc., USA
SOURCE: PCT Int. Appl., 176 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010799	A1	20010215	WO 2000-US21257	20000803 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6492553	B1	20021210	US 1999-368213	19990804 <--
EP 1212269	A1	20020612	EP 2000-955355	20000803 <--

EP 1212269	B1	20041027			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI, LT, LV, FI, RO, MK, CY, AL					
JP 2003506420	T	20030218	JP 2001-515272		20000803 <--
AT 280744	T	20041115	AT 2000-955355		20000803
ES 2230143	T3	20050501	ES 2000-955355		20000803
HK 1046897	A1	20050415	HK 2002-108269		20021115
PRIORITY APPLN. INFO.:			US 1999-368213	A	19990804
			US 1998-73007P	P	19980129
			US 1998-98404P	P	19980831
			US 1998-98708P	P	19980901
			US 1998-101056P	P	19980918
			WO 1999-US1923	A2	19990129
			WO 2000-US21257	W	20000803

OTHER SOURCE(S): CASREACT 134:178141; MARPAT 134:178141

GI



I

AB The title process comprises, e.g., Ugi condensation of N-protected anthranilic acids, amines, aldehydes, and an isocyanide followed by deprotection and cyclization. Thus, 2-(BocMeN)C6H4CO2H, imidazole-1-propanamine, PhCH2CH2CHO, and an isocyanide were combined to give title compound I.

IT 325954-15-2P 325954-16-3P 325954-17-4P
325954-22-1P 325954-24-3P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of oxoazacycloalkanes and analogs)

RN 325954-15-2 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-butyl-2,3-dihydro-2-oxo-α-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 325954-16-3 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 2,3-dihydro-5,6-dimethoxy-2-oxo-N-

(phenylmethyl)-α-propyl- (9CI) (CA INDEX NAME)



RN 325954-17-4 HCAPLUS
CN 1H-Benzimidazole-1-acetamide, 2,3-dihydro-5,6-dimethyl-α-[2-(methylthio)ethyl]-2-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 325954-22-1 HCAPLUS
CN 1H-Benzimidazole-1-acetamide, N-butyl-2,3-dihydro-2-oxo-α-(2-phenylethyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 325954-24-3 HCAPLUS
CN 1H-Benzimidazole-1-acetamide, N-butyl-2,3-dihydro-6-methoxy-2-oxo-α-(2-phenylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:819473 HCAPLUS
DOCUMENT NUMBER: 134:5159
TITLE: Preparation of tripeptoid analogs as serine protease inhibitors
INVENTOR(S): Gyorkos, Albert C.; Spruce, Lyle W.
PATENT ASSIGNEE(S): Cortech, Inc., USA
SOURCE: U.S., 107 pp., Cont-in-part of U. S. Ser. No. 761,190.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 18
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6150334	A	20001121	US 1997-985201	19971204 <--
US 5618792	A	19970408	US 1994-345820	19941121 <--
US 5807829	A	19980915	US 1996-761190	19961206 <--
CA 2272548	A1	19980611	CA 1997-2272548	19971205 <--
WO 9824806	A2	19980611	WO 1997-US21636	19971205 <--
WO 9824806	A3	19981015		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9855894	A	19980629	AU 1998-55894	19971205 <--
AU 734615	B2	20010621		
EP 954526	A2	19991110	EP 1997-952232	19971205 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1247542	A	20000315	CN 1997-180392	19971205 <--
TR 9901681	T2	20000321	TR 1999-1681	19971205 <--
JP 2001507679	T	20010612	JP 1998-525656	19971205 <--
JP 3220169	B2	20011022		
JP 2001192398	A	20010717	JP 2000-197432	19971205 <--
HU 200100669	A2	20010828	HU 2001-669	19971205 <--
TR 200103270	T2	20030321	TR 2001-200103270	19971205 <--
RU 2217436	C2	20031127	RU 1999-114606	19971205 <--
US 6037325	A	20000314	US 1998-69823	19980430 <--

US 6001813	A	19991214	US 1998-90046		19980603 <--
NO 9902734	A	19990802	NO 1999-2734		19990604 <--
MX 9905240	A	20000531	MX 1999-5240		19990604 <--
PRIORITY APPLN. INFO.:			US 1994-345820	A2	19941121
			US 1996-761190	A2	19961206
			US 1996-698575	A1	19960815
			US 1996-760916	A	19961206
			US 1996-761313	A	19961206
			US 1996-762381	A	19961206
			US 1996-771317	A	19961206
			US 1997-984881	A	19971204
			US 1997-984884	A	19971204
			US 1997-985056	A	19971204
			US 1997-985201	A	19971204
			US 1997-985298	A	19971204
			JP 1998-525656	A3	19971205
			WO 1997-US21636	W	19971205

OTHER SOURCE(S): MARPAT 134:5159

GI



I



II

AB Tripeptides I [X, Y = O, N, or S, provided that at least one of X or Y = N; R1 = (un)substituted (C5-12)aryl, (C5-12)arylalkyl, (C5-12)arylalkenyl, fused (C5-12)aryl-cycloalkyl, alkyl- or alkenyl-fused (C5-12)aryl-cycloalkyl optionally comprising one or more heteroatoms selected from N, S, or non-peroxide O; R2, R3 = H or alkyl; A = CO, NHCO, SO2, O2C, or CH2; R4 = H, alkyl, alkenyl, cycloalkyl, aryl, or arylalkyl (with provisos)] were prepared as serine protease inhibitors, including inhibitors of human neutrophil elastase. Thus, peptide I (Cbz = benzyloxycarbonyl) (CE-2072) was prepared and showed Ki = 0.025 nM for inhibition of elastase.

IT 208846-93-9P, CE 2234

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tripeptoid analogs as serine protease inhibitors)

RN 208846-93-9 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:366135 HCAPLUS

DOCUMENT NUMBER: 133:4595

TITLE: Preparation of N-pyrrolidinylmethylalkanoamides and analogs as CCR-3 receptor antagonists

INVENTOR(S): Rogers, Daniel Harry; Saunders, John; Williams, John Patrick

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: Ger. Offen., 50 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19955794	A1	20000531	DE 1999-19955794	19991119 <--
CA 2350903	A1	20000602	CA 1999-2350903	19991111 <--
WO 2000031032	A1	20000602	WO 1999-EP8665	19991111 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9915520	A	20010717	BR 1999-15520	19991111 <--
EP 1131288	A1	20010912	EP 1999-972623	19991111 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO					
TR 200101398	T2	20010921	TR 2001-200101398		19991111 <--
HU 200104364	A2	20020429	HU 2001-4364		19991111 <--
JP 2002530374	T	20020917	JP 2000-583860		19991111 <--
JP 3593037	B2	20041124			
AU 763960	B2	20030807	AU 2000-13825		19991111 <--
GB 2343893	A	20000524	GB 1999-27227		19991117 <--
GB 2343893	B	20020109			
FR 2786185	A1	20000526	FR 1999-14495		19991118 <--
US 6166015	A	20001226	US 1999-442656		19991118 <--
IT 99TO1009	A1	20010521	IT 1999-TO1009		19991119 <--
IT 1307900	B1	20011119			
ES 2158814	A1	20010901	ES 1999-2547		19991119 <--
ES 2158814	B1	20020316			
ZA 2001003942	A	20020815	ZA 2001-3942		20010515 <--
NO 2001002411	A	20010516	NO 2001-2411		20010516 <--
IN 2001CN00693	A	20050304	IN 2001-CN693		20010518
PRIORITY APPLN. INFO.:			US 1998-109297P	P	19981120
			WO 1999-EP8665	W	19991111

OTHER SOURCE(S): MARPAT 133:4595
GI



I

AB Title compds. [I; R4 = CHR1Z1Z2R2; R1 = H or alkyl; R2 = (hetero)aryl; Z = NZ3R3 or N+RZ3R3 X-; R = (un)substituted alkyl; R3 = (hetero)aryl; X- = pharmaceutically acceptable anion; Z1 = (un)substituted NHCO and Z2 = (heteroatom-interrupted)(oxo)alkylene, etc.; Z1 = (un)substituted NHCONH, -NHSO2, -NHCO2, etc. and Z2 = bond, (heteroatom-interrupted)(oxo)alkylene, alkenylene, alkynylene] were prepared Thus, I (R4 = CH2NHR5, Z = NCH2C6H3Cl2-2,3)(II; R5 = H) was amidated by 3-[4-(4-methoxyphenyl)-2-pyrimidinyl]propionic acid (preparation each given) to give II [R5 = COCH2CH2Z2C6H4(OMe)-4, Z2 = pyrimidine-2,5-diyl]. Data for biol. activity of I were given.

IT 270912-02-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-pyrrolidinylmethylalkanoamides and analogs as CCR-3 receptor antagonists)

RN 270912-02-2 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[[1-[(3,4-dichlorophenyl)methyl]-3-pyrrolidinyl]methyl]-5,6-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 270912-01-1
CMF C23 H26 Cl2 N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L9 ANSWER 10 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:84617 HCAPLUS
DOCUMENT NUMBER: 132:122625
TITLE: Preparation of substituted benzimidazole antiviral agents
INVENTOR(S): Yu, Kuo-long; Civiello, Rita Lee; Krystal, Mark R.; Kadow, Kathleen F.; Meanwell, Nicholas A.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004900	A1	20000203	WO 1999-US12398	19990720 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2338147	A1	20000203	CA 1999-2338147	19990720 <--
AU 9950809	A1	20000214	AU 1999-50809	19990720 <--
AU 741946	B2	20011213		
EP 1098644	A1	20010516	EP 1999-935302	19990720 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002521334	T	20020716	JP 2000-560893	19990720 <--
US 2003139450	A1	20030724	US 2002-289829	20021107 <--
US 6908936	B2	20050621		
US 2005038085	A1	20050217	US 2004-934921	20040903

US 7030140 B2 20060418
PRIORITY APPLN. INFO.: US 1998-93387P P 19980720
US 1999-354958 B1 19990716
WO 1999-US12398 W 19990720
US 2002-289829 A3 20021107
OTHER SOURCE(S): MARPAT 132:122625
GI



I



II

AB The title compds. [I and II; R1-R8 = H, alkyl, NO2, etc.; X = straight, branched or cyclic C2-12 alkyl, alkenyl, alkynyl; Y = (un)substituted Ph, dioxolane, pyridine, etc.; XY = CH2Ph, CH2COPh, CH2CHOHPh, etc.; Z = (CR12R13)n; n = 1-4; R12, R13 = H, straight, branched or cyclic alkyl], useful in the treatment of viral infections, particularly, for the treatment of respiratory syncytial virus infection, were prepared Thus, coupling 1-(1H-benzimidazol-2-ylmethyl)-1H-benzotriazole with 2-dimethylaminoethyl chloride hydrochloride in the presence of NaH in THF afforded 23% I [Z = CH2: XY = (CH2)2NMe2; R1-R8 = H] which showed 100% HEp-2 cell protection against RSV at 4 μg/mL.

IT 256365-87-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted benzimidazole antiviral agents)

RN 256365-87-4 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 2-(1H-benzotriazol-1-ylmethyl)-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:672796 HCAPLUS
DOCUMENT NUMBER: 131:299286
TITLE: Preparation of amidine compounds as Xa inhibitors
INVENTOR(S): Katoh, Susumu; Yokota, Katsuyuki; Hayashi, Mikio
PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
SOURCE: PCT Int. Appl., 280 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9952895	A1	19991021	WO 1999-JP1900	19990409 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2327488	A1	19991021	CA 1999-2327488	19990409 <--
AU 9931677	A	19991101	AU 1999-31677	19990409 <--
AU 752588	B2	20020926		
SG 74717	A1	20000822	SG 1999-1654	19990409 <--
EP 1070714	A1	20010124	EP 1999-913608	19990409 <--
EP 1070714	B1	20040804		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO				
TR 200002904	T2	20010221	TR 2000-200002904	19990409 <--
BR 9910122	A	20011016	BR 1999-10122	19990409 <--
HU 200101137	A2	20011028	HU 2001-1137	19990409 <--
NZ 508101	A	20021220	NZ 1999-508101	19990409 <--
RU 2201927	C2	20030410	RU 2000-128036	19990409 <--
AT 272630	T	20040815	AT 1999-913608	19990409
JP 2000136190	A	20000516	JP 1999-103432	19990412 <--
JP 3283485	B2	20020520		
US 6562828	B1	20030513	US 2000-647847	20001006 <--
NO 2000005083	A	20001208	NO 2000-5083	20001009 <--
ZA 2000006430	A	20010725	ZA 2000-6430	20001108 <--
IN 2000CN00627	A	20050304	IN 2000-CN627	20001109
US 2004006099	A1	20040108	US 2003-386458	20030313

PRIORITY APPLN. INFO.: JP 1998-116233 A 19980410
JP 1998-237869 A 19980825
WO 1999-JP1900 W 19990409
US 2000-647847 A3 20001006

OTHER SOURCE(S): MARPAT 131:299286
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. R1R2NCR:NR3 [wherein R1, R2 and R3 are the same or different and each represents hydrogen, hydroxy, lower alkyl or aryl; and R represents formulas Q, Q1, and Q2; A = OCH2, OCH2CH2, SO2NH, ; R4 = H, Cl; R5 = H, CO2H, COOEt, COOMe; B = C6H5CH2SO2, CH2CH2OH, 4-pyridyl, 4-quinolinyl, 4-(2,6-dimethylpyridyl), 4-(2-methylpyridyl), 4-imidazolyl; G = 4-CH2N(4-COC6H4COOH)C6H4O, CH2O, CH2N(COCOOEt);F = (un)substituted aryl; n = 1, 2; D = arylcarbamoyl, OMe, H, C6H5CH2; etc.], stereoisomers, and salts thereof or prodrugs of the same are prepared and tested as factor Xa inhibitors and anticoagulants and usable in preventing and/or treating diseases caused by blood coagulation or thrombi. Thus, the title compound I was prepared

IT 247131-15-3P 247131-65-3P 247131-66-4P
247131-67-5P 247132-26-9P 247134-03-8P
247134-50-5P 247134-51-6P 247134-52-7P
247141-93-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amidine compds. as Xa inhibitors)

RN 247131-15-3 HCAPLUS

CN Benzoic acid, 4-[[[[5-(aminoiminomethyl)-1-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-1H-benzimidazol-2-yl]methyl][4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]amino]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 247131-65-3 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[[5-(aminoiminomethyl)-2-[[4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenoxy]methyl]-1H-benzimidazol-1-yl]acetyl]amino]methyl]-, methyl ester, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 247131-66-4 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[[5-(aminoiminomethyl)-2-[[4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenoxy]methyl]-1H-benzimidazol-1-yl]acetyl]amino]methyl]-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 247131-67-5 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[[5-[(hydroxyamino)iminomethyl]-2-[[4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenoxy]methyl]-1H-benzimidazol-1-yl]acetyl]amino]methyl]-, methyl ester, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 247132-26-9 HCAPLUS
CN Acetic acid, [[[[5-(aminoiminomethyl)-1-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-1H-benzimidazol-2-yl]methyl][4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]amino]sulfonyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 247134-03-8 HCAPLUS
CN Benzoic acid, 4-[[[[5-(aminoiminomethyl)-1-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-1H-benzimidazol-2-yl]methyl][4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247134-50-5 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[[5-(aminoiminomethyl)-2-[[4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenoxy]methyl]-1H-benzimidazol-1-yl]acetyl]amino]methyl]-, methyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247134-51-6 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[[5-(aminoiminomethyl)-2-[[4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenoxy]methyl]-1H-benzimidazol-1-yl]acetyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247134-52-7 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[[5-[(hydroxyamino)iminomethyl]-2-[[4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenoxy]methyl]-1H-benzimidazol-1-yl]acetyl]amino]methyl]-, methyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 247141-93-1 HCAPLUS
CN Benzoic acid, 4-[[[[5-(aminoiminomethyl)-1-[2-oxo-2-[(1-phenylethyl)amino]ethyl]-1H-benzimidazol-2-yl]methyl][4-[[1-(1-iminoethyl)-

4-piperidinyl]oxy]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



IT 247132-62-3P 247132-63-4P 247132-64-5P
247133-58-0P 247133-59-1P 247133-60-4P
247133-61-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amidine compds. as Xa inhibitors)

RN 247132-62-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[[5-cyano-1-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-1H-benzimidazol-2-yl]methyl][(phenylmethoxy)carbonyl]amino]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247132-63-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[[5-cyano-1-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-1H-benzimidazol-2-yl]methyl][4-(methoxycarbonyl)benzoyl]amino]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247132-64-5 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[[[5-(aminoiminomethyl)-1-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-1H-benzimidazol-2-yl]methyl][4-(methoxycarbonyl)benzoyl]amino]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247133-58-0 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[[5-cyano-1-[2-[[[trans-4-(methoxycarbonyl)cyclohexyl]methyl]amino]-2-oxoethyl]-1H-benzimidazol-2-yl]methoxy]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B

—OBu-t

RN 247133-59-1 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[[5-(aminoiminomethyl)-1-[2-[[[trans-4-(methoxycarbonyl)cyclohexyl]methyl]amino]-2-oxoethyl]-1H-benzimidazol-2-yl]methoxy]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B

—OBu-t

RN 247133-60-4 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[[5-[imino(methylamino)methyl]-1-[2-[[[trans-4-(methoxycarbonyl)cyclohexyl]methyl]amino]-2-oxoethyl]-1H-benzimidazol-2-yl]methoxy]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B

—OBu-t

RN 247133-61-5 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[[5-[(hydroxyamino)iminomethyl]-1-[2-[[[trans-4-(methoxycarbonyl)cyclohexyl]methyl]amino]-2-oxoethyl]-1H-benzimidazol-2-yl]methoxy]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B

—OBu-t

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:617950 HCAPLUS
DOCUMENT NUMBER: 131:258916
TITLE: Method for production of coloring substances and new compounds
INVENTOR(S): Kobayashi, Suguru; Kato, Takashi
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11263918	A	19990928	JP 1998-65897	19980316 <--
PRIORITY APPLN. INFO.:			JP 1998-65897	19980316

OTHER SOURCE(S): MARPAT 131:258916
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The substances useful as photog. sensitizing dyes, are obtained by linking a dehydrocondensable group-containing colorant with a counter colorant compound in the presence of P compound such as R1R2PO(OR3) (R1 = aryl; R2 = aryl or living aryloxy group; R3 = aryloxy living group together with the bonding O) in a solvent. Thus, adding a solution of 11 mg KOH in 1 mL water to 100 mg compound I, adding 20 mL DMSO, mixing with 53 mg tetrabutylammonium bromide for 1 h, combining with a solution of 115 mg compound II and C6H5P(O)(C6H4NO2-4)2 in 10 mL DMSO and 100 mg mol. sieve 4A, mixing at room temperature for 20 h and working up gave compound III.

IT 226919-23-9P 244793-36-0P
RL: IMF (Industrial manufacture); MOA (Modifier or additive use); PREP (Preparation); USES (Uses)
(photog. sensitizers; dehydrocondensation reaction in manufacture of bimol. linked dyes for photog. sensitizers)

RN 226919-23-9 HCAPLUS
CN Benzothiazolium, 2-[3-[5,6-dichloro-1-[2-[[3-[6-chloro-2-[3-[5-chloro-1-ethyl-1,3-dihydro-3-(4-sulfobutyl)-2H-benzimidazol-2-ylidene]-1-propenyl]-3-ethyl-1H-benzimidazolium-1-yl]-1-oxopropyl]amino]ethyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene]-1-propenyl]-3-ethyl-5-phenyl-, inner salt, bromide (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 244793-36-0 HCAPLUS
CN Benzothiazolium, 2-[3-[5,6-dichloro-1-[[[3-[6-chloro-2-[3-[5-chloro-1-ethyl-1,3-dihydro-3-(4-sulfobutyl)-2H-benzimidazol-2-ylidene]-1-propenyl]-3-ethyl-1H-benzimidazolium-1-yl]-1-oxopropyl]amino]methyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene]-1-propenyl]-3-ethyl-5-phenyl-, bromide (9CI) (CA INDEX NAME)



● Br^-

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L9 ANSWER 13 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:511140 HCAPLUS
DOCUMENT NUMBER: 131:157771
TITLE: Preparation of five-membered, benzo-condensed heterocycles as antithrombotics
INVENTOR(S): Ries, Uwe; Hauel, Norbert; Mihm, Gerhard; Priepke, Henning; Binder, Klaus; Stassen, Jean Marie; Wienen, Wolfgang; Zimmermann, Rainer
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Kg, Germany
SOURCE: PCT Int. Appl., 250 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9940072	A1	19990812	WO 1999-EP537	19990128 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19804085	A1	19990805	DE 1998-19804085	19980203 <--
DE 19834325	A1	20000217	DE 1998-19834325	19980730 <--
CA 2319494	A1	19990812	CA 1999-2319494	19990128 <--
AU 9927201	A	19990823	AU 1999-27201	19990128 <--
EP 1060166	A1	20001220	EP 1999-907437	19990128 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002502844	T	20020129	JP 2000-530502	19990128 <--

PRIORITY APPLN. INFO.: DE 1998-19804085 A 19980203

DE 1998-19834325 A 19980730
WO 1999-EP537 W 19990128

OTHER SOURCE(S): MARPAT 131:157771

GI



I



HCl II

AB Title compds. [I; R = 5-C6H5SO2NH, 6-C6H5SO2NH, 5-C6H5NHSO2, 5-C6H5SO2N(CH2COOEt), 5-C6H5SO2N(CH3), 5-C6H5N(CH2CH2CH2COOEt)CO, 5-C6H5, CH3N(C6H5)CO, 8; R1 = H, 7-CH3, 3-Br, 3-EtO; R2 = C(:NH)NH2; A = CH2, NH; X = CH, MeN, EtOCOCH2CH2N, O, S, NCH2CO2H; Y = N, CH, CH:CH; Z = CH, N; dotted bond = single, double in relation to X; A is attached at 2,or 8 position depending on the heterocyclic ring] and their tautomers, stereoisomers, mixts. and their physiol. compatible salts with inorg. or organic acids or bases are prepared and title compds in which R2 is a cyano group, present valuable intermediate products for the production of the remaining compds. of the general formula I, with R2 is amidino, which have valuable pharmacol. properties, especially an antithrombotic activity. Thus, the title compound II was prepared

IT 236415-43-3P 236415-45-5P 236415-78-4P
236415-85-3P 236415-88-6P 236415-94-4P
236416-01-6P 236416-02-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of five-membered benzo-condensed heterocycles as antithrombotics)

RN 236415-43-3 HCAPLUS

CN Glycine, N-[[2-[[4-(aminoiminomethyl)phenyl]methyl]-5-[[2-(dimethylamino)ethyl](phenylsulfonyl)amino]-1H-benzimidazol-1-yl]acetyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 236415-45-5 HCAPLUS
CN Glycine, N-[[2-[[4-(aminoiminomethyl)phenyl]methyl]-5-[[2-(dimethylamino)ethyl](phenylsulfonyl)amino]-1H-benzimidazol-1-yl]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 236415-78-4 HCAPLUS
CN Glycine, N-[4-[2-[[4-(aminoiminomethyl)phenyl]methyl]-5-[[2-(dimethylamino)ethyl](methylsulfonyl)amino]-1H-benzimidazol-1-yl]-1-oxobutyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 236415-85-3 HCAPLUS
CN Glycine, N-[[2-[[4-(aminoiminomethyl)phenyl]methyl]-5-[[2-(diethylamino)ethyl](phenylsulfonyl)amino]-1H-benzimidazol-1-yl]acetyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 236415-88-6 HCAPLUS
CN Glycine, N-[[2-[[4-(aminoiminomethyl)phenyl]methyl]-5-[[2-(diethylamino)ethyl](phenylsulfonyl)amino]-1H-benzimidazol-1-yl]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 236415-94-4 HCAPLUS
CN Glycine, N-[[2-[[4-(aminoiminomethyl)phenyl]methyl]-5-[[(1-methyl-2-piperidinyl)methyl](phenylsulfonyl)amino]-1H-benzimidazol-1-yl]acetyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 236416-01-6 HCAPLUS
CN Glycine, N-[[2-[[4-(aminoiminomethyl)phenyl]methyl]-5-[[(1-methyl-2-piperidinyl)methyl](phenylsulfonyl)amino]-1H-benzimidazol-1-yl]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 236416-02-7 HCAPLUS
CN Glycine, N-[[2-[[4-(aminoiminomethyl)phenyl]methyl]-5-[[[2-(dimethylamino)ethyl]amino]carbonyl]-1H-benzimidazol-1-yl]acetyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT 236417-38-2P 236417-39-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation of five-membered benzo-condensed heterocycles as antithrombotics)

RN 236417-38-2 HCAPLUS
CN Glycine, N-[[2-[(4-cyanophenyl)methyl]-5-[(phenylsulfonyl)amino]-1H-benzimidazol-1-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 236417-39-3 HCAPLUS
CN Glycine, N-[[2-[(4-cyanophenyl)methyl]-5-[[(1-methyl-2-piperidinyl)methyl](phenylsulfonyl)amino]-1H-benzimidazol-1-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 14 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:394350 HCAPLUS
DOCUMENT NUMBER: 129:68032
TITLE: Preparation of oxadiazole peptide analogs as serine protease inhibitors
INVENTOR(S): Gyorkos, Albert; Spruce, Lyle W.
PATENT ASSIGNEE(S): Cortech, Inc., USA; Gyorkos, Albert; Spruce, Lyle W.
SOURCE: PCT Int. Appl., 187 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 18
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824806	A2	19980611	WO 1997-US21636	19971205 <--
WO 9824806	A3	19981015		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW

RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 5801148	A	19980901	US 1996-771317		19961206 <--
US 5807829	A	19980915	US 1996-761190		19961206 <--
US 5861380	A	19990119	US 1996-760916		19961206 <--
US 5869455	A	19990209	US 1996-761313		19961206 <--
US 5891852	A	19990406	US 1996-762381		19961206 <--
US 5998379	A	19991207	US 1997-985056		19971204 <--
US 6001811	A	19991214	US 1997-984884		19971204 <--
US 6015791	A	20000118	US 1997-984881		19971204 <--
US 6150334	A	20001121	US 1997-985201		19971204 <--
CA 2272548	A1	19980611	CA 1997-2272548		19971205 <--
AU 9855894	A	19980629	AU 1998-55894		19971205 <--
AU 734615	B2	20010621			
EP 954526	A2	19991110	EP 1997-952232		19971205 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

BR 9713684	A	20000328	BR 1997-13684		19971205 <--
JP 2001507679	T	20010612	JP 1998-525656		19971205 <--
JP 3220169	B2	20011022			
HU 200100669	A2	20010828	HU 2001-669		19971205 <--
RU 2217436	C2	20031127	RU 1999-114606		19971205 <--
NO 9902734	A	19990802	NO 1999-2734		19990604 <--
MX 9905240	A	20000531	MX 1999-5240		19990604 <--
US 2003060418	A1	20030327	US 2001-928117		20010810 <--
US 6656910	B2	20031202			

PRIORITY APPLN. INFO.:	US 1996-760916	A	19961206
	US 1996-761190	A	19961206
	US 1996-761313	A	19961206
	US 1996-762381	A	19961206
	US 1996-771317	A	19961206
	US 1997-984881	A	19971204
	US 1997-984884	A	19971204
	US 1997-985056	A	19971204
	US 1997-985201	A	19971204
	US 1997-985298	A	19971204
	US 1994-345820	A2	19941121
	WO 1997-US21636	W	19971205

OTHER SOURCE(S): MARPAT 129:68032

GI



I



II



III

AB The present invention relates to certain substituted oxadiazole, thiadiazole and triazole peptide analogs I [X, Y = independently O, S, (un)substituted N; Z = serine protease binding moiety, preferably a human neutrophil elastase binding moiety; R1 = (un)substituted alkyl, alkenyl, alkynyl; OH, amino, alkylamino, dialkylamino, cycloalkyl, alkylcycloalkyl, alkenylcycloalkyl, cycloalkenyl, alkylcycloalkenyl, alkenylcycloalkenyl, C5-12 aryl, C5-12 arylalkyl, C5-12 arylalkenyl, fused C5-12 arylcycloalkyl, alkyl fused C5-12 arylcycloalkyl] which are useful as inhibitors of serine proteases. Thus, Swern oxidation of reduced pseudopeptide II (Z = PhCH2O2C), prepared in 8 steps from 3S-(benzyloxycarbonylamino)-2-acetoxy-4-methylpentanenitrile, 3-methylphenylacetic hydrazide, and Z-Val-Pro-OH, gave 74% desired oxadiazole III. III inhibited human neutrophil elastase with IC50 = 0.025 nM in an in vitro assay.

IT 208846-93-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxadiazole peptide analogs as serine protease and human neutrophil elastase inhibitors)

RN 208846-93-9 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 15 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:579714 HCAPLUS
DOCUMENT NUMBER: 127:248130
TITLE: Preparation of N-[4-(4-benzimidazolyl)hexahydrodiazepino-2-arylbutyl]benzamides as histamine and tachykinin receptor antagonists
INVENTOR(S): Maynard, George D.; Kane, John M.; Kudlacz, Elizabeth M.; Dalton, Christopher R.; Santiago, Braulio; Bratton, Larry D.
PATENT ASSIGNEE(S): Hoechst Marion Roussel, Inc., USA
SOURCE: PCT Int. Appl., 176 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9730991	A1	19970828	WO 1997-US1601	19970129 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2246994	A1	19970828	CA 1997-2246994	19970129 <--
CA 2246994	C	20020430		
AU 9722531	A	19970910	AU 1997-22531	19970129 <--
AU 708738	B2	19990812		
EP 888338	A1	19990107	EP 1997-905700	19970129 <--
EP 888338	B1	20041117		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1211248	A	19990317	CN 1997-192383	19970129 <--
BR 9710712	A	19990817	BR 1997-10712	19970129 <--
JP 2000505083	T	20000425	JP 1997-530170	19970129 <--
AT 282609	T	20041215	AT 1997-905700	19970129
ZA 9701321	A	19970826	ZA 1997-1321	19970217 <--
TW 440565	B	20010616	TW 1997-86101884	19970218 <--
NO 9803829	A	19981020	NO 1998-3829	19980820 <--

PRIORITY APPLN. INFO.:			
	US 1996-604590	A	19960221
	US 1997-781997	A	19970106
	WO 1997-US1601	W	19970129

OTHER SOURCE(S): MARPAT 127:248130
GI



I



II

AB Title compds. [I; R2 = Z1CH2CHR1CH2NMeCOZ2R; R = H, 1,2,4-triazol-4-yl or (5-substituted) 1-tetrazolyl; R1 = (un)substituted Ph, -naphthyl, -pyridyl, -thienyl; R3 = H or 1-3 of halo, alkyl, alkoxy; R4 = H, alkyl, (CH2)pR5, alkoxyalkyl, etc.; R5 = 2-furyl, 2-pyridyl, etc.; Z1 = hexahydro-1,4-diazepine-1,4-diyl; Z2 = (un)substituted phenylene; p = 1 or 2] were prepared as histamine and tachykinin receptor antagonists (no data). Thus, 4-[1-(2-ethoxyethyl)-2-benzimidazolyl]hexahydro-1,4-diazepine was N-alkylated by MeO2SOCH2CH2CHR1CH2NMeCOR (R = 3,4,5-trimethoxyphenyl, R1 = C6H4F-4)(preparation each given) to give title compound II.

IT 192941-18-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-[4-(4-benzimidazolyl)hexahydrodiazepino-2-arylbutyl]benzamides as histamine and tachykinin receptor antagonists)

RN 192941-18-7 HCAPLUS

CN 1H-1,4-Diazepine-1-carboxylic acid, hexahydro-4-[1-[2-(methylamino)-2-oxoethyl]-1H-benzimidazol-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	102.45	274.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-11.70	-11.70

STN INTERNATIONAL LOGOFF AT 13:45:59 ON 17 JAN 2007